Skip to content
OmniaBio Full Color Logo

Learn more about our CDMO facilities

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
  • Contact
OmniaBio Full Color Logo

Learn more about our CDMO facilities

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
  • Contact
Our Leadership Team
-

Ken Harris

Kenneth Harris

Ken Harris

Chief Strategy Officer and Head of AI

Ken Harris has dedicated over three decades to revolutionizing health care. With a profound expertise spanning 35 years in the field, Ken has been at the forefront of innovation and leadership in technology, medical devices and therapeutics.

In his most recent role, Ken spearheaded the academic medicine and public health vertical within Amazon’s $90 billion annual revenue group - Amazon Web Services. He charted new territories by developing the business from its inception, leading a dynamic team comprised of principal trusted health care advisors, physician advisors, health informaticists, and health care IT architects.

Prior to his tenure at Amazon, Ken's illustrious career showcased his adeptness in executive leadership. He notably founded and successfully took public a pioneering cell and gene therapy precision medicine company, marking a milestone in the advancement of cell therapy in cardiovascular medicine. Additionally, he played C-level and Board roles with a Stanford University cell and gene therapy start-up, and led Pall Corporation’s global biomedical business for 13 years (now a Danaher company).

Ken's commitment to staying at the forefront of health care innovation is evidenced by his completion of a certification in Healthcare AI/ML from Harvard Medical School. Ken serves on several U.S. federal advisory groups, including most recently the National Institutes of Health’s Advanced Research Program Agency for Healthcare, and the newly launched Coalition for Health AI, a 501(C) organization to drive safe and valid deployment of AI in health care.

OmniaBio Footer Logo in Full Color

© 2025 OmniaBio   |   Privacy Policy

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
Contact Us
Scroll to Top